📄 medicine

Comparative Outcomes of Direct Impella Use vs. Intra-Aortic Balloon Pump (IABP)-to- Impella Escalation Strategy in Cardiogenic Shock: Insights from the National Inpatient Sample

In patients with cardiogenic shock, initiating Impella support directly rather than escalating from an IABP is associated with similar in-hospital mortality but significantly shorter hospital stays, lower costs, fewer transfusions, and lower rates of subsequent durable LVAD implantation or heart transplantation.

Original authors: Xiaojia Lu, Aditi Patel, Romani Wahba, Peng Cai, Omar Khalil, Racha Ghousaini, Kirollos Gabrah, Inna Tchoukina, Melissa Smallfield, Michael C Kontos, Keyur B Shah, Pengyang Li

Published 2026-07-07

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Xiaojia Lu, Aditi Patel, Romani Wahba, Peng Cai, Omar Khalil, Racha Ghousaini, Kirollos Gabrah, Inna Tchoukina, Melissa Smallfield, Michael C Kontos, Keyur B Shah, Pengyang Li

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine your heart is the engine of a car, and sometimes, that engine sputters and fails, leaving the car unable to move. This is called cardiogenic shock. When this happens, doctors need to put a temporary "jump starter" on the engine to keep the car running while they figure out a permanent fix.

For a long time, the most common jump starter was a device called an IABP (Intra-Aortic Balloon Pump). It's like a small balloon inside the main fuel line that inflates and deflates to help push blood forward. It's easy to put in and safe, but it's a bit like a gentle nudge—it doesn't provide a huge boost of power.

Recently, a more powerful jump starter called Impella has become popular. Think of Impella as a high-performance electric motor that actively pulls blood out of the heart and pushes it out to the body. It does a much stronger job of unloading the heart's workload.

The Big Question
Doctors have been using two different strategies when a patient's heart fails:

The "Direct" Strategy: Put in the powerful Impella motor immediately.
The "Escalation" Strategy: Start with the gentle IABP balloon. If the patient doesn't get better, then swap it out for the powerful Impella motor.

The researchers wanted to know: Is it better to start with the big gun (Impella) right away, or to try the small gun (IABP) first and upgrade if needed?

How They Studied It
The team looked at a massive database of over 100,000 patients in the US who were hospitalized with heart failure shock between 2016 and 2022. They compared the "Direct" group against the "Escalation" group. To make sure the comparison was fair, they used a statistical trick (like matching twins) to ensure both groups had similar patients with similar levels of sickness.

What They Found
Here is the breakdown of the results, translated into everyday terms:

Survival Rates (The Most Important Part):
The study found that it didn't matter which strategy you used for survival. Whether patients got the Impella immediately or started with the IABP and upgraded later, the number of people who survived the hospital stay was essentially the same. The "Escalation" strategy did not save more lives than the "Direct" strategy.
The Cost and Time (The Efficiency Part):
This is where the two strategies differed significantly.
- The "Escalation" Group: Patients who started with the IABP and then switched to Impella stayed in the hospital much longer (about 6 days longer on average) and the hospital bills were much higher (roughly $250,000 more per patient).
- The "Direct" Group: Patients who got the Impella right away went home sooner and the total cost was lower.
Why was the "Escalation" group more expensive?
The researchers noted that patients in the "Escalation" group were more likely to need major, expensive future procedures, like getting a permanent artificial heart pump (LVAD) or a heart transplant. However, even when the researchers looked only at patients who got the specific, larger surgical Impella devices, the "Direct" group still had shorter stays and lower costs. This suggests that the act of switching devices itself (or the delay in getting strong support) adds up in time and money.

The Bottom Line
Think of it like fixing a broken pipe. If you know you need a heavy-duty industrial pump to fix the leak, using a small garden hose first and then swapping to the industrial pump later doesn't fix the leak any faster or save more lives. In fact, it just takes more time and costs more money to make the switch.

The study concludes that for patients with severe heart shock, starting with the powerful Impella device immediately seems to be a more efficient choice. It gets patients home faster and saves money, without changing the odds of survival compared to the "try the small one first" approach.

Important Note: This study looked at hospital records, not a controlled experiment where patients were randomly assigned. The doctors chose the strategy based on what they thought was best at the time. However, the data strongly suggests that waiting to upgrade might be an unnecessary detour for many patients.

Technical Summary: Comparative Outcomes of Direct Impella Use vs. IABP-to-Impella Escalation in Cardiogenic Shock

Problem Statement
Cardiogenic shock (CS) is a high-mortality syndrome characterized by inadequate tissue perfusion due to severe cardiac dysfunction. While temporary mechanical circulatory support (tMCS) devices are utilized to stabilize hemodynamics, the optimal strategy for device selection and sequencing remains debated. Historically, the intra-aortic balloon pump (IABP) was the standard due to its safety and ease of insertion, though its mortality benefit has been questioned following the IABP-SHOCK II trial. Conversely, the Impella percutaneous microaxial flow pump offers more potent hemodynamic support by actively unloading the left ventricle. In clinical practice, two primary strategies exist: the direct use of Impella as initial support, or an escalation strategy where Impella is deployed only after IABP failure or clinical deterioration. Despite the prevalence of these approaches, real-world comparative data evaluating the outcomes of these two specific strategies is limited.

Methodology
This study utilized a retrospective cohort design using the 2016–2022 National Inpatient Sample (NIS), the largest all-payer inpatient database in the United States.

Population: Adult patients (≥18 years) with a primary diagnosis of cardiogenic shock (ICD-10 code R57.0). Patients receiving extracorporeal membrane oxygenation (ECMO) were excluded to focus on non-ECMO tMCS strategies.
Exposure Groups: Patients were stratified into two groups based on the sequence of device use:
1. Direct Impella Use: Impella implanted without prior IABP support ( $n=10,007$ ).
2. Escalation Impella Use: Impella implanted after initial IABP support during the same hospitalization ( $n=700$ ).
Subgroup Analysis: The cohort was further stratified by etiology: Acute Myocardial Infarction (AMI)-associated CS and non-AMI-associated CS. A sensitivity analysis was also conducted focusing specifically on surgically implanted Impella 5.0/LD/5.5 devices.
Statistical Approach: To mitigate selection bias, Propensity Score Matching (PSM) was performed in a 1:1 ratio using a nearest-neighbor algorithm with a 0.2 caliper. Outcomes were compared before and after matching.
Outcomes Measured:
- Primary: In-hospital mortality, rates of orthotopic heart transplantation (OHT), and durable left ventricular assist device (LVAD) implantation.
- Secondary: Hospital length of stay (LOS), total hospitalization costs, and blood transfusion rates.

Key Results
The study included 10,707 patients. After propensity score matching, 698 patients remained in each group, with balanced baseline characteristics.

Mortality: There was no significant difference in in-hospital mortality between the direct Impella group and the IABP-to-Impella escalation group, both in the unmatched (39.4% vs. 39.0%, $P=0.86$ ) and matched cohorts (38.4% vs. 39.1%, $P=0.826$ ). This finding held true across AMI and non-AMI subgroups.
Resource Utilization and Costs: The direct Impella strategy was consistently associated with superior efficiency metrics:
- Length of Stay (LOS): Significantly shorter in the direct group (13.17 days vs. 19.22 days in matched cohort, $P<0.001$ ).
- Total Costs: Significantly lower in the direct group ($478,526 vs. $725,276 in matched cohort, $P<0.001$ ).
- Transfusions: The direct group required fewer blood transfusions (15.8% vs. 20.5% in matched cohort, $P=0.026$ ).
Advanced Therapies: The escalation group demonstrated higher rates of bridging to durable therapies. In the matched cohort, the escalation group had higher rates of LVAD implantation (7.7% vs. 3.0%, $P<0.001$ ) and OHT (4.9% vs. 1.9%, $P=0.003$ ).
Sensitivity Analysis (Impella 5.0/LD/5.5): In the subset of patients receiving surgically implanted devices, direct use again showed no mortality difference but significantly shorter LOS (39.01 vs. 47.16 days, $P=0.041$ ) and lower costs ($1.33M vs. $1.66M,$ P=0.047$) compared to the escalation strategy.

Key Contributions

Real-World Evidence: This is the first study to utilize a large, nationally representative database to directly compare the "direct Impella" versus "IABP-to-Impella escalation" strategies in a broad CS population.
Strategy vs. Device: The findings suggest that the timing and sequencing of device initiation are critical factors. The data indicates that escalating from IABP to Impella does not confer a survival advantage over early direct Impella use but is associated with increased resource consumption.
Etiological Consistency: The benefits of direct use regarding LOS and cost were consistent across both AMI and non-AMI etiologies, suggesting the findings are applicable regardless of the underlying cause of shock.

Significance and Claims
The authors conclude that while the escalation strategy is a common real-world approach, it does not yield clinical survival benefits over direct Impella use. Instead, the escalation strategy is linked to longer hospital stays and higher healthcare costs. The paper posits that these inefficiencies may stem from delays in achieving full circulatory support, cumulative device costs, and the higher likelihood of patients in the escalation group requiring downstream advanced therapies (LVAD/OHT).

The study emphasizes that early optimization of device strategy based on the patient's shock phenotype should be considered at admission to ensure appropriate resource allocation. The authors suggest that when Impella support is indicated, early direct use may be a more efficient strategy than an initial IABP trial followed by escalation. However, they maintain a modest tone, acknowledging that the study is retrospective, subject to unmeasured confounding (such as hemodynamic severity and institutional practice patterns), and limited to in-hospital outcomes. The paper calls for future research to develop risk stratification tools that integrate patient characteristics with device selection to refine clinical guidelines.

Technical Summary: Comparative Outcomes of Direct Impella Use vs. IABP-to-Impella Escalation in Cardiogenic Shock

More like this